Autolus is among the sea of biotechs seeking to improve on first-generation T-cell therapies but has hit bumps in the road, leading to a 20% reduction in staff and the hunt for a partner on a drug candidate earlier this year. But now, the company has the validation of a deal with a high-profile partner. Moderna has signed on to leverage Autolus' technology in its mRNA therapies against four immuno-oncology targets. Soucre: Fierce Biotech 2/8/2021